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ABSTRACT 
Analysis of VEGF, PDGF and bFGF Production by Adipose Stem Cells Incorporated in 
Fibrin-Rich Blood Clots 
 
by 
Kelsy R. Siegel 
 
Surgical repair of some connective tissues, such as tendon, has a high failure rate. 
Exploration of surgical adjuvants, including platelet-rich plasma, bioactive scaffolds, and cell 
delivery, are being explored in an effort to enhance tissue healing. The purpose of this study 
is to quantify the capture and concentration of platelets (PLTs) during fibrin clot (FC) 
formation and to evaluate how the immunoreactivity and secretion of growth factors VEGF, 
PDGF and bFGF from FCs is modulated by the addition of allogeneic adipose stem cells 
(ASCs). Platelet concentration during fibrin clot formation was determined by quantifying 
pre-clot and post-clot serum samples.  Fibrin clot formation concentrated 92% (p<0.01) of 
the available PLTs in whole blood.  Two experimental conditions and one control condition 
were evaluated over two weeks in vitro.  FCs made from human whole blood without ASCs, 
FC(-)ASC, were compared with FCs with ASCs incorporated, FC(+)ASC, and a control 
group of synthetic polyethylene glycol gels with ASCs incorporated, PEG(+)ASCs.  All 
conditions were examined for secretion and retention of VEGF, PDGF, and bFGF. Analysis 
of platelet retention for FCs made with this device was performed. ELISA analysis showed 
significantly higher (p<0.01) secretion of VEGF in FC(+)ASC compared to FC(-)ASC or 
PEG(+)ASC. In contrast, FC(-)ASC produced soluble PDGF, and the addition of ASCs 
results in decreased soluble PDGF with concomitant increases in PDGF immunoreactivity of 
 vi
ASCs.  Soluble bFGF levels were low in FC(-)ASC, and were found to increase at early 
time-points in FC(+)ASC.  Furthermore, bFGF immunoreactivity could be detected in 
FC(+)ASC while no bFGF immunoreactivity is present in FC(-)ASC or PEG(+)ASC. These 
findings provide evidence that FCs made through this described method concentrate a high 
proportion of available platelets that are known to secrete growth factors over time.  The 
incorporation of ASCs to this system results in increased growth factor production, 
particularly of VEGF. Enhanced growth factor production localized to a surgical repair site 
may enhance the healing response and strengthen connective tissue to lower the incidence of 
re-tear.
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Introduction 
 
Despite recent advances in surgical techniques for connective tissue repair, surgeons 
continue to explore the use of bioactive factors to enhance tissue healing and improve 
surgical outcomes1-3.  The use of biologic agents may be particularly useful and effective for 
the treatment of compromised tissue. Efforts for this type of augmentation include the use of 
fibrin clot (FC), platelet-rich plasma (PRP), synthetic scaffolds and stem cells in the effort to 
increase localized production of beneficial growth factors4-9. 
Fibrin is a biopolymer found in blood that is involved in the coagulation cascade. 
Fibrin clots can be formed from peripheral blood and are comprised of a fibrin meshwork 
that can capture and contain platelets, act as a reservoir for cells, growth factors and other 
bioactive factors, and provide an effective delivery system for cells10,11. Fibrin clots have 
been shown to enhance the surgical repair of tissue with poor healing capacity12-14. In 1988, 
Arnoczky et al. described the application of a fibrin clot to aid healing of meniscal defects in 
the avascular zone in a canine model. Additional clinical studies have also demonstrated 
increased healing of meniscal tears with the application of fibrin clot including complete 
radial tears in the avascular zone and horizontal cleavage tears13,15-17. More recently, fibrin 
clot has been demonstrated in a caprine model to histologically improve healing of the intra-
articular ACL reconstruction segment and to decrease the signal intensity on MRI, 
suggesting possible improvement of graft healing and maturation18. Furthermore, the addition 
of FC to allograft in human ACL reconstruction has been shown to reduce the amount of 
tunnel widening at one year14. 
The use of PRP as a method to concentrate and deliver bioactive factors also has been 
explored3.  The increased concentration of platelets in PRP provides elevated levels of 
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localized growth factors important for healing of compromised tissue19. Some of these 
growth factors, including vascular endothelial growth factor (VEGF)19,20, platelet-derived 
growth factor (PDGF)19,20, and fibroblast growth factor (FGF)20 are rapidly degraded and 
have a short half-life21, limiting the potential clinical usefulness of PRP. Thus, there is a need 
to develop sustained delivery of growth factors.  
 Many types of stem cells express and secrete growth factors. Adipose tissue has 
proven to be a rich source of multipotent adult stem cells, similar to bone-marrow derived 
mesenchymal stem cells (BM-MSCs)22.  Adipose derived stem cells (ASCs) have many of 
the same differentiation capabilities as BM-MSCs, while being significantly more abundant 
and readily isolated through standard liposuction procedures23. Additionally, ASCs have been 
found to express growth factors VEGF, PDGF, and bFGF, which have been extensively 
studied in regards to therapeutic application for damaged tissues24,25.  Recent studies indicate 
that allogeneic ASCs have the potential to improve healing in compromised tendon, ligament 
and other tissues without eliciting an immune response19-21.  
 The purpose of this study is to evaluate the secretion and retention of growth factors 
VEGF, PDGF, and bFGF from human peripheral blood FCs over two weeks in vitro, and to 
determine how levels are modulated by the addition of allogenic ASCs.  It is hypothesized 
that FC formation will efficiently capture available platelets in whole blood, cells in the clot 
will secrete growth factors and VEGF, PDGF and bFGF will be retained in the FC over two 
weeks, and that the incorporation of ASCs into FCs will effectively increase the secretion 
and retention of these growth factors. 
3 
Methods and Materials 
Platelet capture: 
From 10 human volunteers, 35mL of whole blood was obtained; 5mL was evaluated for pre-
clot cell count evaluation and the remaining 30mL was placed into a sterile container with a 
sintered glass cylinder supported by the lid (ClotMaster Hula Cup, Pierce Surgical Corp., 
Vermont) for FC formation.  The FC was removed and 5ml of the post-clot serum was sent 
for post-clot formation cell count evaluation for platelets, red blood cells (RBCs) and white 
blood cells (WBCs).  The cell counts for pre-clot whole blood and post-clot serum samples 
were compared using the DxH 800 Coulter Counting Cellular Analysis System (Beckman 
Coulter Inc, Brea CA).  All work with human subjects in this study was approved by the 
UCSB Human Subjects Committee prior to performing the study (protocol # 4-16-0523).  
Informed consent was provided to all human subjects who volunteered in this study.  
 
Cell lines and culture: 
Human ASCs isolated from lipoaspirate, transduced with a constitutive mCherry–luciferase 
reporter plasmid and selected for by previously established methods26 were expanded in 
culture and frozen in liquid nitrogen for storage. Upon thaw, passage 4-6 cells were 
suspended in media consisting of 60% Dulbecco’s modified Eagle’s medium (DMEM; Life 
Technologies) with 10% fetal bovine serum (FBS;Atlas Biologicals, Fort Collins, CO) and 
40% MesenPRO medium (Life Technologies).  Cells and media were centrifuged 1200 g for 
3 minutes and resulting cell pellets were resuspended in 3:2 DMEM +10% FBS:MesenPro 
media and switched to 100% MesenPRO 24–48 h later.  Cells were plated in 225-cm2 cell 
culture flasks (Sigma-Aldrich; CLS431082
4 
) at a density of 2.2x103cells/cm2 where they were left to expand at 37°C. Media was 
replenished every two days until cells reached 80% confluence, at which point cells were 
lifted for seeding in blood clots or PEG gels.  
 
FC Formation and ASC Incorporation:  
Prior to FC formation, cells were washed with 10mL of phosphate buffered saline (PBS) and 
dissociated with 10mL TrypLE Select (Life Technologies; A1285901) at 37oC for 5–10 min.  
The TrypLE solution was inactivated with a 1:1 dilution of MesenPRO and centrifuged at 
1200 g for 3 minutes. Cells were resuspended in 2mL DMEM and counted with a 
hemocytometer to confirm a density of 5x106 cells per mL.  Whole human blood was 
collected from 10 allogeneic volunteers (80mL/volunteer), 20mL of which was deposited 
into each clotting device.  For each volunteer, four FCs were created: two day zero FCs with 
and without ASCs and two FCs with and without ASCs to continue on for sampling through 
two weeks.  FCs to be seeded with ASCs were each supplemented with 1x107 cells in 2mL 
DMEM.  FCs without ASCs were supplemented with 2mL of DMEM only.  Immediately 
after whole blood was collected and supplemented with cells or media alone, the clot 
formation cups were placed on a rotator at room temperature for 10 minutes at 125rpm. After 
10 minutes, day zero FCs(+/-)ASCs were washed twice with PBS and immediately fixed in 
10mL of 4% paraformaldehyde in 0.1M sodium cacodylate and stored at 4oC until cryo-
preservation. FC(+/-)ASCs to be cultured for two weeks were washed twice with PBS and 
then placed in a 6-well polystyrene plate (Corning Inc., Corning, NY) in 5mL DMEM + 
0.1mg/mL normocin (Invivogen; 50mg/mL) and incubated at 37oC for two weeks.  Media 
(DMEM+normocin) was replenished 24 hours prior to sampling as well as immediately 
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following sampling.  Samples of media were collected at day 1, 3, 7, 9, 12, and 14, snap 
frozen in liquid nitrogen, and stored at -80oC for future enzyme-linked immunosorbent assay 
(ELISA) analysis. At day 14, clots were fixed in 4% paraformaldehyde in 0.1M sodium 
cacodylate and stored at 4oC until cryo-preservation.  
 
Polyethylene Glycol Gel Casting: 
A solution of 4-arm PEG-Thiol (Creative PEGWorks, Chapel Hill, NC; PSB-440) at 10 wt% 
was prepared in 37oC cell culture media. A solution of divinyl sulfone (DVS) crosslinker 
(Sigma-Aldrich) was prepared in 4oC cell culture media. A custom ECM-based peptide was 
synthesized by BioMatik (VnRGD-CGRCGKGGPQVTRGDVFTMPG-K-biotin) and gels 
were functionalized with VnRGD at 80mM concentrations before DVS crosslinker addition. 
After dissociation with TrypLE Select and pelleting, cells were resuspended in PEG/peptide 
solution (1x107 cells/gel) and the DVS crosslinker was added at a 10:1 ratio (DVS:PEG) 
immediately before plating. Approximately 800µL of gel solution was transferred into a 
20mm aluminum ring mold. The PEG(+)ASC solution was left to polymerize for 30 min at 
37oC, after which each gel was placed directly into 5mL DMEM + 0.1mg/mL normocin in 
separate wells of a 6-well polystyrene plate. PEG(+)ASCs were incubated at 37oC for two 
weeks. Media was replenished and samples were taken following the same protocol that was 
outlined for FC(+/-)ASCs above.  
Immunohistochemistry:   
Day 0 and 14 FC(+/-)ASCs (n=10), and control PEG(+)ASCs (n=5) were removed from 4% 
paraformaldehyde solution and washed three times with PBS.  Samples were placed in 10% 
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sucrose in PBS for 2 hours, followed by 20% sucrose for 2 hours, 30% sucrose for 2 hours, 
and 40% sucrose overnight with gentle rotation at 4oC.  Following cryo-protection, samples 
were placed in plastic disposable base molds (ThermoFisher; 41744) with optimal cutting 
temperature (O.C.T.; Tissue-Tek, 4583) embedding medium.  Once embedded in O.C.T., 
clots and gels were frozen with liquid nitrogen without full submersion. 
For immunohistochemical analysis, all samples were embedded in O.C.T. and cut 
into 20µm sections using a cryostat (Leica; CM1850), and mounted onto polysine slides 
(ThermoFisher; P4981-001). Approximately 100 slides were collected from each sample. 
Tissue samples were subjected to a blocking solution consisting of 0.2% Triton X-100 in 1X 
PBS and 5% normal donkey serum (Abcam; ab138579)  for 1 hour at room temperature. 
Cells were stained for 2 hours at 4oC with primary antibodies diluted in the blocking solution 
(See Table 1).  Following primary antibody staining, samples were washed with PBS 3 times 
and stained with secondary antibodies (See Table 1) and Hoechst 33342 (0.0004 mg/mL; 
Life Technologies) for 1 h in the dark at room temperature.  Secondary antibody-only 
controls were performed for all conditions to confirm staining specificity.  Samples were 
mounted under glass cover-slips (ThermoFisher) with 4% n-propyl gallate (Sigma) in 90% 
glycerol mounting media.   
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Table 1: A List of Primary and Secondary Antibodies Used in this Study 
Antibody Species 
Concentration 
(mg/mL) 
Manufacturer 
Catalog 
Number 
VEGF-A 
Rabbit Polyclonal 
(1o) 
0.002 
Thermo Fisher 
Scientific 
PA516754 
PDGF-BB 
Rabbit Polyclonal 
(1o) 
0.0065 Abcam ab23914 
FGF-2 
Rabbit Polyclonal 
(1o) 
0.0005 Abcam ab8880 
mCherry 
Mouse Monoclonal 
(1o) 
0.004 Abcam ab125096 
Alexa Fluor® 
488 
Donkey anti-Rabbit 
(2o) 
0.008 
Thermo Fisher 
Scientific 
A-21206 
Alexa Fluor® 
488 
Donkey anti-Mouse 
(2o) 
0.008 
Thermo Fisher 
Scientific 
A-21202 
 
 
Imaging: 
All imaging of immunohistochemical samples was performed on a Spectral-based Laser 
Scanning Confocal Microscope (Olympus FV1000; Lasers: 405, 440, 488, 514, 559, 633) at 
40x magnification.   All scale bars were included at the time of imaging (scale=50µm).   
 
Growth Factor Quantification: 
The culture media from FC(+/-)ASCs and PEG(+)ASCs was sampled at each time point 24 
hours after being replenished, and snap frozen in liquid nitrogen for ELISA analysis. ELISA 
kits for detecting vascular endothelial growth factor (VEGF-A; Life Technologies, 
KHG0111), platelet-derived growth factor (PDGF-BB; Abcam, ab100624), and basic 
fibroblast growth factor (FGF-2; Abcam, ab99979), were optimized and used according to 
the manufacturer’s protocol to quantify the concentration of each growth factor present in the 
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media at each time point.  Positive controls were included and implemented for each 
condition.   
 
Statistical Analysis: 
Statistical analysis was performed using a paired two-tailed Student’s t-test for pre-clot and 
post-clot cell counts and all subsequent assays.  All data are displayed as mean ± standard 
error. The threshold of statistical significance was set to p≤0.05 for all comparisons.  
 
Results 
Platelet capture: 
The 10 volunteers (5 female and 5 male) had a mean age of 39.8 years. The mean platelet 
count of whole blood was 187.80x103/μL, WBC 5.52x103/μL and RBC 4.47x103/μL. The 
mean platelet count of the post-clot plasma decreased significantly to 4.40x106/μL (p<0.01) 
while neither the post-clot plasma WBC count (4.79x103) nor the RBC count (4.59x103/μL) 
changed significantly. By comparing the pre-clot platelet count to the post-clot platelet count 
it was estimated that FC fibrin clot captured and concentrated an average of 92% of the 
available platelets (See Table 2).  
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Table 2: Platelet Retention Levels From Pre-clot to Post-clot Formation 
 Age & Gender Mean SD 
Subjects 52M 36M 34F 51M 29F 31F 29F 55M 26F 55M   
Whole Blood:             
WBC 6.9 6.3 5.9 5.3 5.4 3.4 5.1 5.9 6.6 4.4 5.52 1.05 
RBC 5.1 4.8 4.4 4.6 4.2 3.6 4.2 5.0 4.1 4.8 4.47 0.46 
PLT 119 190 158 186 249 272 177 222 154 151 187.8 47.43 
Post-clot Plasma: 
WBC 5.7 5.2 5.4 4.8 4.4 2.1 5.0 5.4 6.1 3.8 4.79 1.15 
RBC 5.2 4.8 4.5 4.7 4.3 3.7 4.4 5.1 4.2 4.9 4.59 0.45 
PLT 3 1 1 3 4 20 3 4 2 3 4.4 5.58 
Table 2. Cell counts from 5 ml of pre-clot whole blood and 5 ml of post-clot serum samples. 
  
VEGF immunoreactivity and secretion: 
Immunohistochemical analysis of VEGF indicates higher expression in FC with 
ASCs incorporated than in FC without ASCs, and PEG with ASCs.  The presence of ASCs 
was confirmed by the expression of the mCherry marker (Figure 1 A-E). No VEGF 
immunoreactivity was detected in FC(-)ASC at day 0 or day 14 (Figure 1A, C - green). 
However, VEGF immunoreactivity was observed in FC(+)ASC at day 0 and day 14 localized 
to ASCs (Figure 1B, D - green).  PEG(+)ASC at day 0 and day 14 showed no VEGF 
immunoreactivity within ASCs as indicated by a lack of signal in Figure 1E  (green). White 
blood cell nuclei (blue) are also observed in FC(+/-)ASC, and can be distinguished from 
ASCs based on absence of mCherry signal in addition to being smaller with a more rounded 
morphology (Figure 1A-E).  
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  VEGF secretion from FC(+)ASC was consistently elevated when compared to FC(-
)ASC (p<0.001), and PEG(+)ASC (p<0.001) (Figure 1F) as determined by ELISA.  The 
average concentrations for FC(+)ASC for days 1, 3, 7, 9, 12, and 14 were 607.10+/-
2.29pg/mL to 803.83+/-4.27pg/mL (error=SEM).  The average concentrations for FC(-)ASC 
for days 1, 3, 7, 9, 12, and 14 were 18.75+/-5.96pg/mL to 322.625+/-2.5414pg/mL. The 
average concentrations for PEG(+)ASC for days 1, 3, 7, 9, 12, and 14 were 0pg/mL to 
249.23+/-11.25pg/mL.  
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Figure 1: VEGF 
immunoreactivity and 
secretion. (A) FC(-)ASC 
at day 0. (B) FC(+)ASC 
at day 0. (C) FC(-)ASC at 
day 14. (D) FC(-)ASC at 
day 14. (E) PEG(+)ASC 
at day 14. (F) Secretion 
of VEGF by FC(-)ASC 
(black solid line), 
FC(+)ASC (black 
segmented line), and 
PEG(+)ASC (gray line) 
was quantified by ELISA 
at day 1,3,7,9,12, and 14. 
Significance compares 
FC(+)ASC to the control: 
PEG(+)ASC 
(***p<0.001;**p<0.01, 
*p<0.05).  Error is 
displayed as SEM. 
VEGF, vascular 
endothelial growth factor; 
FC, fibrin clot; ASC, 
adipose stem cell; PEG, 
polyethylene glycol gel. 
Scale bar = 50 um for all 
images.  
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PDGF immunoreactivity and secretion: 
 
PDGF immunoreactivity was detected in both white blood cells and ASCs in both FC 
without ASCs, FC with ASCs and PEG with ASCs.  The FC(-)ASC sample  showed 
decreasing PDGF immunoreactivity from day 0 to day 14 as indicated by an absence of 
PDGF signal at day 14 (Figure 2A, C - green). In contrast, PDGF immunoreactivity was 
detected in the day 14 sample of FC(+)ASC, with the PDGF signal localized to ASCs only as 
indicated by colocalizaton with the mCherry reporter signal (Figure 2B, D - green, red). 
PEG(+)ASC showed no PDGF immunoreactivity at day 0 and day 14 as indicated by a lack 
of PDGF signal (Figure 2E - green).  
  Based on data from ELISA analysis, PDGF secretion from FC(-)ASC was 
consistently elevated when compared to FC(+)ASC (p<0.05), and PEG(+)ASC (p<0.001) 
(Figure 2F).  The average concentrations for FC(+)ASC for days 1, 3, 7, 9, 12, and 14 were 
between 0pg/mL to 123.77+/-1.786pg/mL. The average concentrations for FC(-)ASC for 
days 1, 3, 7, 9, 12, and 14 were 25.77+/-0.48pg/mL to 130.37+/-1.90pg/mL. The average 
concentrations for PEG(+)ASC for days 1, 3, 7, 9, 12, and 14 were 0pg/mL to 15.31+/-
0.84pg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13
 
 
Figure 2: PDGF 
immunoreactivity and 
secretion.  (A) FC(-
)ASC at day 0. (B) 
FC(+)ASC at day 0. (C) 
FC(-)ASC at day 14. 
(D) FC(+)ASC at day 
14. (E) PEG(+)ASC at 
day 14. (F) Secretion of 
PDGF by FC(+)ASC 
(black solid line), FC(-
)ASC (black segmented 
line), and PEG(+)ASC 
(gray line) was 
quantified by ELISA at 
day 1,3,7,9,12, and 14. 
Significance compares 
FC(+)ASC, and FC(-
)ASC to the control: 
PEG(+)ASC 
(***p<0.001;**p<0.01, 
*p<0.05). Error is 
displayed as SEM.  
PDGF, platelet-derived 
growth factor; FC, fibrin 
clot; ASC, adipose stem 
cell; PEG, polyethylene 
glycol gel. Scale bar = 
50 um for all images.  
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bFGF immunoreactivity and secretion: 
 
Immunohistochemical (IHC) analysis of bFGF indicated higher immunoreactivity in 
FC with ASCs incorporated than in FC without ASCs or in PEG with ASCs.  FC(+)ASC 
showed bFGF immunoreactivity at day 0 and day 14 as indicated by bFGF signal that is 
localized to ASCs only as indicated by colocalization with the mCherry reporter signal 
(Figure 3B, D – green, red).  FC(-)ASC show no bFGF immunoreactivity at day 0 or day 14 
as indicated by a lack of bFGF signal (Figure 3A, C - green). PEG(+)ASC also showed no 
bFGF immunoreactivity at day 0 or day 14 from ASCs as indicated by a lack of bFGF signal 
(Figure 3E - green).  
  Based on ELISA analysis, bFGF secretion from FC(+)ASC was elevated when 
compared to FC(-)ASC at days 1, 3 and 9 (p<0.05), but not at days 12 and 14 (Figure 3F).  
PEG(+)ASC show a significant spike in bFGF (p<0.001) secretion compared to FC(+)ASC 
and FC(-)ASC between days 0 and 3, and then drop to levels at or below those of FC(+)ASC 
by day 7.  The average concentrations for FC(+)ASC for days 1, 3, 7, 9, 12, and 14 were 
379.88+/-13.64pg/mL to 1599.21+/-14.68pg/mL. The average concentrations for FC(-)ASC 
for days 1, 3, 7, 9, 12, and 14 were 189.35+/-15.03pg/mL to 587.15+/-9.47pg/mL.  The 
average concentrations for PEG(+)ASC for days 1, 3, 7, 9, 12, and 14 were 510.55+/-
12.23pg/mL to 5667.72+/- 11.25pg/mL.  
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Figure 3: bFGF 
immunoreactivity and 
secretion. (A) FC(-)ASC 
at day 0. (B) FC(+)ASC at 
day 0. (C) FC(-)ASC at 
day 14. (D) FC(+)ASC at 
day 14. (E) PEG(+)ASC at 
day 14. (F) Secretion of 
bFGF by FC(+)ASC 
(black solid line), FC(-
)ASC (black segmented 
line), and PEG(+)ASC 
(gray line) was quantified 
by ELISA at day 
1,3,7,9,12, and 14. 
Significance compares 
FC(+)ASC to the control: 
PEG(+)ASC 
(***p<0.001;**p<0.01, 
*p<0.05).  Error is 
displayed as SEM.  bFGF, 
basic fibroblast growth 
factor; FC, fibrin clot; 
ASC, adipose stem cell; 
PEG, polyethylene glycol 
gel. Scale bar = 50 um for 
all images.  
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Discussion 
 Despite the long history of FC being used to augment tissue healing in the orthopedic 
literature, to our knowledge, this is the first study to determine platelet capture during FC 
formation. Our finding of a platelet capture rate averaging 92% compares favorably to prior 
studies that have demonstrated platelet capture rates of traditional PRP ranging from 17-
80%27. Additionally, FC formation using this technique did not significantly change the 
WBC count in the post clot serum indicating that the FC did not selectively capture and 
concentrate available WBCs. These findings indicate that this technique for fibrin clot 
formation creates a platelet rich fibrin scaffold (PRFS) without concentrating WBCs.  Since 
FCs capture platelets, they produce similar growth factors to PRP but also provide a 
structural support and a scaffold for cellular ingrowth, while serving as a reservoir for growth 
factor release over time from incorporated cells18,28. The dense nature of the PRFS also 
provides a structural integrity that allows for arthroscopic suturing over a repair site29. 
 The use of biologic and synthetic scaffolds to deliver stem cells for therapeutic 
benefit has become increasingly widespread.  A major challenge faced when seeding cells in 
a synthetic scaffold is mimicking an environment that will provide an adequate niche for cell 
survival and proliferation.  Common synthetic scaffolds including polypropylene, 
polyurethane, and polytetrafluoroethylene can produce mechanical stresses, illicit host 
response, and inhibit integration into recipient tissue16,30.  In contrast to synthetic materials, 
biologic materials may provide a more suitable environment to adipose stem cells by 
promoting sustained proliferation, in addition to growth factor recruitment and secretion9.  
The use of biomaterials such as decellularized ECM and PRP has been explored for tissue 
healing, but have been found to be sub-optimal in regards to cell survival, localization, and 
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growth factor retention9,31. Our findings demonstrate that in vitro, FC secretes VEGF, PDGF 
and bFGF over 14 days. Additionally, VEGF expression from ASCs was increased 
substantially when incorporated in a FC. This underscores the possibility that FCs may be an 
enhanced method for delivering cells and their bioproducts to a localized area.  Our findings 
indicate that the FC may act as an effective well for cells to attach and express growth factors 
that may provide therapeutic benefit to biologically compromised tissue.     
Previous studies have shown that in varying conditions, ASCs have receptors for 
VEGF, PDGF, and bFGF in vitro as well as in vivo, and can effectively express these growth 
factors through intra- and extra-cellular signalling24,25.  The interaction between the fibrin 
matrix of different materials and endothelial cells has been investigated thoroughly in studies 
to characterize how the expression of VEGF, PDGF, and bFGF is modulated32-34. To our 
knowledge, this is the first study to characterize the secretion and retention of VEGF, PDGF, 
and bFGF from ASCs incorporated in the fibrin matrix of an allogeneic FC. 
 
Interaction between VEGF, PDGF, and Fibrin 
ASCs have been found to express VEGF without exogenous supplementation in 
vitro35.  We found significantly higher secretion of soluble VEGF in FC(+)ASC compared to 
FC(-)ASC or PEG(+)ASC.  In addition, IHC analysis indicates that VEGF immunoreactivity 
of FC(+)ASC is elevated compared to the other conditions. These results may be suggestive 
of a synergistic interaction between ASCs and the fibrin matrix of the FC. Factors within the 
FC may increase ASC expression of VEGF, which could initiate a positive feedback loop 
that in turn promotes increased cell surface VEGF receptors and subsequent enhancement of 
VEGF immunoreactivity in ASC32. The VEGF secretion data collected here supports 
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previous findings that ASCs secrete levels of VEGF that are comparable to BM-MSCs and 
endothelial cells upon interaction with a synthetic fibrin matrix36.  Based on significantly 
elevated VEGF secretion from FC(+)ASC when compared to FC alone (FC-ASC) and ASC 
alone (PEG+ASC), the environment of the FC may be conducive to VEGF production from 
ASCs.    
Upon clot formation, the alpha granules of platelets are activated and quickly release 
anabolic cytokines like PDGF37.  Exogenous PDGF has been found to bind with high affinity 
to PDGF receptors on the surface of ASCs25.  Fibrin matrices have been shown to slowly 
release PDGF and VEGF over time38, suggesting that once these anabolic cytokines are 
released from platelets, free PDGF may be steadily supplemented to ASCs that are attached 
to the FC, which can readily be bound by cell surface receptors. This conclusion is supported 
by the enhanced immunoreactivity of PDGF in FC(+)ASC than in FC(-)ASC and 
PEG(+)ASC conditions.  Lower levels of PDGF in the surrounding media of FC(+)ASC, as 
confirmed by ELISA analysis, further supports that ASCs may bind and retain free PDGF 
that is being released from the platelets in the FC.  
Furthermore, when PDGF is bound to its cell surface receptor on ASCs, intracellular 
signaling with VEGF is activated39.  VEGF is known to be the primary initiator of 
angiogenesis, but has been shown to be insufficient in establishing mature and complex 
vasculature40.  PDGF is known to initiate blood vessel maturation by recruiting smooth 
muscle cells to developing vasculature, but is incapable in initiating nascent vessels40. These 
characteristics led to the finding that dual delivery of VEGF and PDGF to a synthetic 
scaffold results in a complex and mature vascular network40. Studies have found that PDGF 
bound to human cells significantly up-regulates VEGF expression within the cell39,41,42.  
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While this study does not evaluate the angiogenic potential of the FC(+)ASC construct, it is 
an intriguing possibility for the future investigation of the therapeutic application of this 
novel cell delivery system.  
 
Interaction between VEGF, bFGF, and Fibrin  
Previous studies have found that undifferentiated and differentiated ASCs express 
bFGF receptors without exogenous supplementation25,43.  This study found that the 
concentration of bFGF may be modulated by the interaction between ASCs and a fibrin 
matrix.  Secreted bFGF from endothelial cells has been found to bind to fibrinogen and fibrin 
with high affinity, allowing for a large degree of retention in a synthetic fibrin matrix32,44.  
The observed bFGF immunoreactivity in ASCs incorporated in a FC may be due to an 
interaction with the fibrin matrix of the FC.  
The secretion data provides evidence that the fibrin matrix of the FC is providing 
attachment and eventual release of bFGF, which may be available to then bind to ASCs and 
activate expression of endogenous bFGF. The process of embedding ASCs into PEG can be 
harsh, and may be sufficient to illicit a stress response from the cells.  It has been shown that 
bFGF is secreted by cells immediately following injury45, which may explain the initial spike 
in secretion of bFGF from PEG(+)ASC at day 0. The immediate drop in secretion and lack of 
bFGF immunoreactivity in PEG(+)ASC could be evidence that PEG does not retain adequate 
amounts of bFGF to promote subsequent up-take by ASCs. Ultimately, the fibrin matrix of 
the FC may be retaining and potentially enhancing bFGF up-take by ASCs.  This binding of 
soluble bFGF could effectively increase bFGF receptor formation on ASCs, which has been 
found to promote cellular stability when combined with VEGF receptors34,46. 
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 Previous studies have found that growth factors are more effective when expressed in 
combination, and in some instances, their expression is inhibited in the absence of certain 
growth factors39,47,48.  VEGF and bFGF have been studied extensively for their synergistic 
relationship39,44,46,47.  When supplemented exogenously or endogenously, bFGF has been 
shown to up-regulate VEGF mRNA expressed by endothelial cells49.  Moreover, quiescent 
endothelial cells could not produce VEGF unless supplemented with exogenous or 
endogenous bFGF, which acts both intra- and extracellularly to promote VEGF expression.  
The extracellular signaling of bFGF with VEGF membrane receptors acts to stimulate cell 
proliferation, migration, and up-regulate VEGF mRNA production49,50.  Intracellular bFGF 
signaling is localized to the nucleus and modulates cell proliferation while up-regulating 
VEGF mRNA production from within the cell49,50.  The high bFGF immunoreactivity of 
ASCs when incorporated in a FC may therefore be interacting with cellular VEGF, resulting 
in increased expression of VEGF as confirmed by significant increases in ELISA levels of 
VEGF in FC(+)ASC.  
 
Interaction between PDGF, bFGF, and Fibrin 
 Synergism is also evident between PDGF and bFGF41,51.  PDGF has been found to 
stimulate proliferation and migration of smooth muscle cells that could be beneficial in tissue 
healing51.  PDGF expression is activated by the ERK pathway, which is initiated by tyrosine 
kinase receptors, FGFR-1/2, which in turn are activated by endogenous bFGF51.  ASCs have 
been found to produce bFGF endogenously43.  Exogenous bFGF is also available for cellular 
uptake through heparanase activity in the extracellular matrix of an in vivo environment52, or 
as demonstrated here, from the fibrin matrix of the FC.  In the absence of bFGF, PDGF has 
 21
been found to be significantly down-regulated41, which could subsequently lower VEGF 
expression.  The findings from this study demonstrate that ASCs may exhibit increased 
expression of VEGF when incorporated in a FC due to the presence of endogenous bFGF and 
exogenous PDGF.  This conclusion supports previous findings that indicate a synergistic 
behavior exists between these three growth factors, which may be promoted by the 
environment of the FC.  
 
Conclusions   
This study has demonstrated FC formation binds platelets and releases VEGF, PDGF 
and bFGF over 14 days in vitro. Further, VEGF levels were enhanced in FCs containing 
ASCs.  The addition of ASCs in a FC results in decreased soluble PDGF with concomitant 
increases in PDGF immunoreactivity in ASCs.  Soluble bFGF increased when FCs were 
combined with ASCs, and bFGF immunoreactivity was detected in ASC encapsulated in 
FCs. Whole blood fibrin clots may provide a hospitable environment for ASC attachment and 
expression of VEGF, and bFGF, along with retention of PDGF. Enhanced expression of 
VEGF, PDGF, and bFGF that is localized to a surgical repair site has the potential to 
augment tissue healing. 
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